TY - JOUR T1 - A Novel Diagnostic Test to Screen SARS-CoV-2 Variants Containing E484K and N501Y Mutations JF - medRxiv DO - 10.1101/2021.03.26.21253712 SP - 2021.03.26.21253712 AU - Yanan Zhao AU - Annie Lee AU - Kaelea Composto AU - Marcus H. Cunningham AU - Jose R. Mediavilla AU - Samantha Fennessey AU - André Corvelo AU - Kar Fai Chow AU - Michael Zody AU - Liang Chen AU - Barry N. Kreiswirth AU - David S. Perlin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/29/2021.03.26.21253712.abstract N2 - Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been associated with concerning changes of the virus, including resistance to neutralizing antibodies and increased transmissibility. While the concerning variants are fast spreading in various geographical areas, identification and monitoring of these variants is lagging far behind, due in large part to the slow speed and insufficient capacity of viral sequencing. In response to the unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular assay for rapid and simultaneous identification of E484K and N501Y mutations from nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this tool, we screened a total of 435 clinical NS samples collected from COVID patients at 8 hospitals within the Hackensack Meridian Health network in New Jersey. While B.1.351 and P.1 variants were absent from the current study, our data revealed a dramatic increase in the frequency of E484K over time, underscoring the need for continuous epidemiological monitoring.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the COVID Emergency Research Fund #61315, Hackensack University Medical center; by funds provided to the CDI by Activision Publishing Inc, Suez North America, and by NJ Stands Up to COVID. The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study accessed to SARS-CoV-2 positive nasopharyngeal swab specimens through the Hackensack Meridian Health (HMH) institutional Biorepository under an HMH-IRB approved protocol Pro2018-1022, to screen the signature mutations. This study also accessed de-identified data for time and location of sample collection through the HMH-IRB approved protocol, Pro2020-0342.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable ER -